-
The results of KN026 second-line treatment of HER2-expressing gastric cancer or gastroesophageal junction cancer were published in the internationally renowned journal EJC
Time of Update: 2023-01-01
About KN026 KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can bind two non-overlapping epitopes of HER2 at the same time, resulting in HER2 signal blockade, which is better than the combination of trastuzumab and pertuzumab, such as showing higher affinity, and has a potent tumor suppressor effect in HER2-positive tumor cell lines.
-
TauRx Alzheimer's Disease Drug Approved in China Phase III; dMed-Clinipace as Partner
Time of Update: 2022-05-20
KM Seng (Doctor Xin Guangming) was to bring an effective and accessible Alzheimer's disease (AD) treatment to patients around the world, with China's national medicine With the approval of the New Drug Clinical Trial Application (NMPA), we are one step closer to achieving this goal .
-
The new crown inactivated vaccine of Koxing Zhongwei, a pharmaceutical speed-reading agency, was approved for sale in China
Time of Update: 2021-03-08
(Pharmaceutical Mingkangde) Hainan Hai Pharmaceuticals: Subsidiary Amoxilin Capsules through generic drug consistency evaluation February 7, Hainan Hai Pharmaceuticals announced that its holding subsidiary recently obtained NMPA approved the issuance of the chemical "Amoxilin Capsules" "Drug Supplemental Application Approval Notice." amoxicillin capsules are mainly used for the treatment of infectious diseases in adults and children caused by sensitive bacteria.
-
Shandong Drug Administration issued drug quality sampling results 12 pharmaceutical companies were announced (attached list
Time of Update: 2020-12-12
In order to strengthen drug quality supervision and ensure the safety of public drug use, according to the annual sampling work plan of the provincial drug regulatory bureau, the provincial bureau ha
-
Tianshili sold pharmaceutical commercial assets were questioned, the main products declined, the Yan family has two more enterprises to board A shares
Time of Update: 2020-07-19
Read: Tianshili's performance fell significantly, but at the same time pushed the two companies A-shares listed 21 June , Tasley (600535 SH) received the sofs, mainly from the divestiture of its phar
-
Not yet approved! Guidelines for clinical trials of thorades mono-injectable biosimilar synopsis released
Time of Update: 2020-05-21
[7] Genovese MC, Mckay JD, NasonovEL, etal Interleukin-6 inhibition withtocilizumabsdisease activity yr heuma toidaidd athanostostostodadadadadadadadadaddadd: Thetocilizumabin combination with thetyannis- modifyantirheustyditath Arthritis and rheumatism, 2008, 58 (10): 2968-2980.
-
"Pharmaceutical headlines" fake milk powder past, Yin and Yang company, big head dolls and joint letter
Time of Update: 2020-05-15
(2020/05/15) over-purchase 1000 times medical device "star shares" PeiJia Medical listed today; Hansen class 2 biological new drug HS-20090 injection approved clinical; 1 year total survival rate incr
-
[yaocajun] Hengrui has applied for new drugs to be put on the market again. Zhengda Tianqing "fukewei" has the new year's indications, plus the first heavy imitation. Lilai and AstraZeneca
Time of Update: 2019-09-09
Highlights: 1 It's a happy day for both sides, with new indications and heavy weight of monoclonal antibody; 2 Lilaiqizhumab injection brings new hope for 6 million patients with psoriasis; 3 The lung
